Physician profile
Nivedita Chander
NPI 1356344253
$4,360.06
in general payments reported to CMS, 2019-2025
27 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $349 · 2021: $417 · 2022: $765 · 2023: $130 · 2024: $927 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055 · Education: $95.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.81 |
| Education | $95.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $734.17 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $385.45 | 2022-2025 | |
| Novo Nordisk INC | $364.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $354.54 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $272.73 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $271.41 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $260.97 | 2019-2025 | Farxiga |
| Mallinckrodt Enterprises LLC | $170.95 | 2019 | |
| Ani Pharmaceuticals, INC. | $166.50 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $161.82 | 2022-2025 | |
| Amgen INC. | $161.12 | 2019-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $153.19 | 2019-2024 | Auryxia |
| Ardelyx, INC. | $139.05 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $137.46 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $133.68 | 2019-2023 | Rayaldee |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $92.40 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $67.98 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $64.63 | 2019-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.91 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $40.98 | 2022-2024 | Ultomiris |
| Kowa Pharmaceuticals America, INC. | $36.65 | 2019-2021 | |
| Scpharmaceuticals INC. | $30.41 | 2025 | |
| Pfizer INC. | $27.37 | 2024 | |
| Arbor Pharmaceuticals, INC. | $27.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.76 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $22.13 | 2021 | |
| Melinta Therapeutics, LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nivedita Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.